Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda

Sarah Nabukeera, Joseph Kagaayi, Fredrick Edward Makumbi, Henry Mugerwa, Joseph K B Matovu, Sarah Nabukeera, Joseph Kagaayi, Fredrick Edward Makumbi, Henry Mugerwa, Joseph K B Matovu

Abstract

Background: While the proportion of HIV-positive children (under 15 years) enrolled on antiretroviral therapy (ART) has increased in recent years, up to 60% of children started on ART do not achieve virological suppression. We set out to determine the factors associated with virological non-suppression among children living with HIV receiving ART at a peri-urban HIV care clinic in Kampala, Uganda.

Method: This was a retrospective cohort study conducted at the pediatric HIV/AIDS clinic at the Joint Clinical Research Centre (JCRC) in Kampala, Uganda. Three hundred (300) HIV-positive children (0-14 years) were randomly selected from existing medical records and data on children's socio-demographic and clinical characteristics (age at ART initiation, WHO clinical staging, and ART-induced side effects) were abstracted using a data abstraction form. Virological non-suppression was defined as a viral load ≥1000 copies/Ml of blood after six months of ART initiation. Incident rate ratios (IRRs) were determined as a measure of association between virological non-suppression and child/patient characteristics. The IRRs were obtained via a modified Poisson regression with corresponding 95% confidence intervals (95%CI). All analyses were done using statistical package, Stata version 15.

Results: The overall non-suppression rate among HIV-positive children on ART was 23%. Being at WHO clinical stage 4 at ART initiation [adj. IRR 2.74; 95%CI: 1.63, 4.61] and ART-induced side effects [adj. IRR 1.77; 95%CI: 1.06, 2.97] were significantly associated with non-suppression. Older age at ART initiation (age 5-9 years: [adj. IRR 0.42; 95%CI: 0.28, 0.65]; age 10-14 years: [adj. IRR 0.34; 95%CI: 0.18, 0.64] was less likely to be associated with virological non-suppression.

Conclusion: Nearly a quarter of HIV-positive children on ART had a non-suppressed viral load after six months of treatment. Being at WHO clinical stage 4 at ART initiation and ART-induced side effects were significantly associated with virological non-suppression while older age at ART initiation was protective. Our findings suggest a need for age-specific interventions, particularly those targeting children below five years of age, to improve virological suppression among HIV-positive children receiving ART in this setting.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. United Nations International Children's Fund (UNICEF). Children and AIDS: statistical update. New York: UNICEF; 2017. Available at: . Accessed on: July 13, 2020.
    1. The Joint United Nations Programme on HIV/AIDS. Fact sheet—latest global and regional statistics on the status of the AIDS epidemic. Geneva: UNAIDS; 2017. Available at: . Accessed on July 13, 2020.
    1. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update. 2016. Available at: . Accessed on July 16, 2020.
    1. de Abreu JC, Vaz SN, Netto EM, Brites C. Virological suppression in children and adolescents is not influenced by genotyping, but depends on optimal adherence to antiretroviral therapy. Braz J Infect Dis. 2017;21(3):219–25. 10.1016/j.bjid.2017.02.001
    1. Costenaro P, Penazzato M, Lundin R, Rossi G, Massavon W, Patel D, et al. Predictors of treatment failure in HIV-positive children receiving combination antiretroviral therapy: cohort data from Mozambique and Uganda. J Pediat Inf Dis Soc. 2015;4(1):39–48. 10.1093/jpids/piu032
    1. Boerma RS, Boender TS, Sigaloff KC, Rinke de Wit TF, Van Hensbroek MB, Ndembi N, et al. High levels of pre‐treatment HIV drug resistance and treatment failure in Nigerian children. J Int AIDS Soc. 2016;19(1):21140 10.7448/IAS.19.1.21140
    1. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015;10(2): e0116144 10.1371/journal.pone.0116144
    1. Ministry of Health, Uganda.Consolidated guidelines for prevention and treatment of HIV in Uganda. Ministry of Health; 2018. Available at: . Accessed on July 11, 2020.
    1. Nasuuna E, Kigozi J, Muwanguzi PA, Babirye J, Kiwala L, Muganzi A, et al. Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study. BMC Health Serv Res. 2019;19(1):150 10.1186/s12913-019-3963-y
    1. Nasuuna E, Kigozi J, Babirye L, Muganzi A, Sewankambo NK, Nakanjako D. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18(1):1048 10.1186/s12889-018-5964-x
    1. Uganda Population -Based HIV Impact Assessment, 2016–2017. Ministry of Health Uganda, August2017. Available at: . Accessed on: July 13, 2020.
    1. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014–July 2015. BMC Infect Dis. 2017;17(1):326 10.1186/s12879-017-2428-3
    1. Kityo C, Boerma RS, Sigaloff KC, Kaudha E, Calis JC, Musiime V, et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother. 2017;72(9):2587–95. 10.1093/jac/dkx188
    1. Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, et al. High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial. PLoS One. 2014;9(3): e90772 10.1371/journal.pone.0090772
    1. Van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, Thuma PE, et al. HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS One. 2011; 6(4): e19006 10.1371/journal.pone.0019006
    1. Moyo S, Ncube RT, Shewade HD, Ngwenya S, Ndebele W, Takarinda KC, et al. Children and adolescents on anti-retroviral therapy in Bulawayo, Zimbabwe: How many are virally suppressed by month six? F1000Res. 2020; 9: 191 10.12688/f1000research.22744.1
    1. Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, et al. Adherence to antiretroviral therapy for HIV in sub‐Saharan Africa and Asia: a comparative analysis of two regional cohorts. J Int AIDS Soc. 2017; 20(1):21218 10.7448/IAS.20.1.21218
    1. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. Available at: . Accessed on July 16, 2020.
    1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. 10.7326/0003-4819-133-1-200007040-00004
    1. Chhim K, Mburu G, Tuot S, Sopha R, Khol V, Chhoun P, et al. Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study. AIDS Res. 2018;15(1):20 10.1186/s12981-018-0205-z
    1. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000; 30(Suppl 2): S171–S176. 10.1086/313849
    1. Fonsah JY, Njamnshi AK, Kouanfack C, Qiu F, Njamnshi DM, Tagny CT, et al. Adherence to antiretroviral therapy (ART) in Yaoundé-Cameroon: association with opportunistic infections, depression, ART regimen and side effects. PLoS One. 2017;12(1): e0170893 10.1371/journal.pone.0170893
    1. Joseph Davey D, Abrahams Z, Feinberg M, Prins M, Serrao C, Medeossi B, et al. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa. Int J STD AIDS. 2018;29(6):603–10. 10.1177/0956462417748859
    1. Schlatter AF, Deathe AR, Vreeman RC. The need for pediatric formulations to treat children with HIV. AIDS Res Ther. 2016; 2016: Article ID 1654938. 10.1155/2016/1654938

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj